PT-141: A Signal From Inside the Brain, Not the Blood Vessels

The short version

PT-141, known by its drug name bremelanotide, is a synthetic cyclic peptide built to mimic alpha-melanocyte-stimulating hormone (alpha-MSH), a natural signaling molecule. What sets it apart from many other sexual-health compounds is where it works: PT-141 activates melanocortin receptors — mainly MC4R — concentrated in hypothalamic and limbic brain circuits tied to sexual desire, rather than acting on blood vessels the way erectile-dysfunction pills do.

It is FDA-approved, as an injectable, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Two identical Phase 3 trials found it significantly improved measured sexual desire over placebo ^[20]. It is not approved for men, for postmenopausal women, or for any performance-enhancement use, and material sold as "PT-141 research chemical" sits entirely outside pharmaceutical quality control. This page separates what is approved and trial-tested from what is off-label and anecdotal, and recommends no dose for anyone.

What it is

PT-141 is a seven-amino-acid cyclic peptide, structurally a relative of a tanning peptide called melanotan II, but chemically distinct at its tail end. Its cyclic (ring-closed) structure, built with a lactam bridge between two of its amino acids, is part of what gives it a longer-lasting signal than a simple straight-chain peptide would have. As a messenger, its job is to occupy melanocortin receptors — the same receptor family involved in skin pigmentation, appetite, and sexual motivation — with a strong preference for MC4R, the receptor subtype most concentrated in the hypothalamus.

How it works

PT-141 activates MC4R (and to a lesser extent MC3R) in hypothalamic regions such as the medial preoptic area, engaging dopamine-signaling circuits believed to drive sexual motivation and arousal. That is the key mechanistic distinction from PDE-5 inhibitor drugs, which act peripherally on vascular smooth muscle to increase blood flow: PT-141 is thought to act on the brain's motivational circuitry first, with physical arousal following from that central signal rather than the other way around.

A 2022 brain-imaging study in women with HSDD found that MC4R agonism significantly increased sexual desire for up to 24 hours and changed how the brain processed erotic stimuli, including altered connectivity between the amygdala and insula — regions tied to emotional and interoceptive processing ^[19]. A separate 2025 hamster study, however, found that bremelanotide did not enhance the brain's sexual-reward circuit itself, suggesting its effect on desire and its effect on reward may be separate systems ^[18].

What the research shows

Pivotal efficacy trials. Two identical Phase 3 randomized, placebo-controlled trials (the RECONNECT program), enrolling a combined 1,267 premenopausal women with HSDD, found that an as-needed 1.75 mg subcutaneous dose produced a statistically significant improvement in sexual desire and a reduction in desire-related distress over 24 weeks compared with placebo ^[20].

Long-term extension. A 52-week open-label extension enrolling 684 of those women found no new safety signals and sustained improvements in desire; the most common drug-related side effects were nausea (40.4%), flushing (20.6%), and headache (12.0%) ^[21].

Brain mechanism. The fMRI study described above provided direct neuroimaging evidence that MC4R agonism changes how the brain processes sexual stimuli, supporting the central (brain-first) mechanism proposed for the drug ^[19].

A nuanced negative finding. The 2025 hamster study found that neither low nor high doses of bremelanotide changed melanocortin-receptor activity in the brain's reward pathway, and it did not make sexual interaction more rewarding in that model — a reminder that "increases desire" and "increases reward" are not automatically the same thing ^[18].

Regulatory and pharmacokinetic detail. The approved US prescribing information specifies the 1.75 mg as-needed dose, a maximum of one dose per 24 hours and no more than eight doses per month, a terminal half-life of about 2.7 hours, and a boxed warning about a transient rise in blood pressure ^[22].

Reported effects, cautions & safety

Anecdotal, not clinical evidence — the reports below come from patient-review sites and research-use community discussion, not controlled measurement, and none of them is a recommended dose.

The most commonly described benefit is a felt increase in sexual desire that people describe as starting mentally rather than physically — "wanting" sex again, distinct from the purely physical response reported with vascular-acting drugs. Greater physical arousal and sensitivity, easier or more intense orgasm, and (in off-label male use) spontaneous erections are also frequently reported. Many users note a delayed onset — effects often build over thirty minutes to a few hours and can last well into the next day, which some describe as convenient and others as hard to plan around. A recurring and honestly reported finding is that a meaningful minority feel no benefit at all, sometimes while still experiencing side effects.

On the adverse side, nausea is by far the most common and the most likely reason people stop, typically strongest with the first dose and easing with continued use. Flushing and warmth, headache, and mild injection-site irritation are frequently reported. With repeated frequent dosing, some users describe darkening of skin, gums, or moles — tied to the drug's activity on pigment-related receptors — that some say did not fully fade after stopping.

Cited safety cautions: PT-141 is approved only for premenopausal women with HSDD, and every other population is using it off-label, outside the studied and labeled group ^[22][20]. It causes a short-lived rise in blood pressure, so the label warns against use in uncontrolled hypertension or known cardiovascular disease ^[22]. Nausea affects a large share of users — roughly 40% in long-term data — and is the leading reason for discontinuation ^[21]. Repeated frequent dosing can darken skin, gums, and moles, more so in people with darker skin, and this may not fully reverse ^[22]. An NIH monograph notes bremelanotide has been linked to mild liver-enzyme changes and, rarely, clinically apparent liver injury. Material sold as "PT-141 research chemical" sits outside pharmaceutical quality control, and forensic testing has confirmed unregulated melanocortin-peptide products circulate on the gray market. The same receptor also sits in appetite circuits, so high-frequency dosing reduced food intake and body weight in research settings — a pharmacological side effect, not an approved use. No controlled human data support use during pregnancy or breastfeeding.

Where it fits among the messengers

PT-141 is the only compound on this desk whose primary signal is inside the brain rather than the bloodstream or a peripheral tissue — a genuinely different kind of messenger from semaglutide's gut-hormone mimicry or ipamorelin's pituitary knock. It also carries the most complete regulatory approval and Phase 3 trial record of the two non-semaglutide compounds with an approved indication. See the full side-by-side on the comparison page.